Advertisement
Organisation › Details
ProBioGen AG
ProBioGen is a Berlin-based specialist for developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines with applying proprietary technologies to improve product quality and features. Combining both state-of-the-art development services, based on ProBioGen's CHO.RiGHT® expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with GMP standards (EMA/FDA). ProBioGen has been operational for almost 30 years. At four locations in Berlin, 300 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work. ProBioGen's growth strategy is driven by the expansion of the service value chain through organic growth and potential acquisition. Diversification is a complement driver, while the focus is strict on enabling the development of biopharmaceuticals for tomorrow. *
Start | 2003-07-01 renamed before | |
Group | Minapharm (Group) | |
Predecessor | ProBioGen GmbH Produktions- und Entwicklungsgesellschaft für ..mbH | |
Industry | recombinant protein production in mammalian cells | |
Industry 2 | contract manufacturing (biologicals) | |
Person | Hilbrich, Lutz (Droege Investment 202409– CEO of Halix BV before ProBioGen AG + Sanofi China + Boehringer) | |
Person 2 | Sandig, Volker (ProBioGen 201004 promoted CSO since 2000 at ProBiogGen before Merck US) | |
Region | Berlin | |
Country | Germany | |
Street | 8 Herbert-Bayer-Str. | |
City | 13086 Berlin | |
Tel | +49-30-3229-35-100 | |
Address record changed: 2024-03-20 | ||
Basic data | Employees | C: 51 to 100 (2014-09-09) |
* Document for »About Section«: ProBioGen AG. (3/13/24). "Press Release: ProBioGen Partners with Mapp Biopharmaceutical, Inc. for Groundbreaking Development of Afucosylated Antibody against Marburg Virus Disease Using GlymaxX Technology". Berlin. | ||
Record changed: 2024-09-20 |
Advertisement
More documents for Minapharm (Group)
- [1] Halix B.V.. (9/19/24). "Press Release: Halix Appoints Dr. Lutz Hilbrich as New Chief Executive Officer". Leiden....
- [2] ProBioGen AG. (5/29/24). "Press Release: ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development". Berlin....
- [3] ProBioGen AG. (4/30/24). "Press Release: Change in Management". Berlin....
- [4] ProBioGen AG. (3/27/24). "Press Release: ProBioGen and DioSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever". Berlin....
- [5] ProBioGen AG. (3/13/24). "Press Release: ProBioGen Partners with Mapp Biopharmaceutical, Inc. for Groundbreaking Development of Afucosylated Antibody against Marburg Virus Disease Using GlymaxX Technology". Berlin....
- [6] ProBioGen AG. (1/10/23). "Press Release: ProBioGen Collaborates with Boehringer Ingelheim on DirectedLuck Transposase Technology". Berlin....
- [7] MiGenTra GmbH. (11/29/22). "Press Release: Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa"....
- [8] ProBioGen AG. (2/11/22). "Press Release: ProBioGen Signs a Commercial License Agreement with AstraZeneca Providing their GlymaxX® Technology". Berlin....
- [9] ProBioGen AG. (6/22/21). "Press Release: ProBioGen and Lava Therapeutics N.V. Sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific". Berlin & Utrecht....
- [10] ProBioGen AG. (5/27/21). "Press Release: ProBioGen and Minapharm Pharmaceuticals Incorporate MiGenTra GmbH – a Healthcare Transforming Medicines Company". Berlin & Cairo....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top